CD274 and glioblastoma: PD1/PDL1-antibody (Ab) mediated checkpoint inhibition (CPI) has been transformative in treating several types of solid tumors; however the localization of GBM behind the blood-brain barrier limits Ab access, and CPI trials have been unsuccessful in treating GBM.